He Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
He Zhou has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Fangjian Li
Institute of Hepatobiliary, Pancreatic, and Intestinal Diseases, North Sichuan Medical College, Nanchong, China
2 shared publicationsLin Wu
Department of General Surgery II, Guang’an District People’s Hospital of Guang’an City, Guang’an, China
2 shared publicationsYi Wu
Department of Gastrointestinal Surgery II, Affiliated Hospital of North Sichuan Medical College, Nanchong, China
2 shared publicationsHuafang Hou
The Second Department of Gastrointestinal Surgery, The Affiliated Hospital of North Sichuan Medical College, Nanchong, People’s Republic of China
1 shared publication- Jiayu Xu
School of Clinical Medicine, North Sichuan Medical College, Nanchong, Sichuan, China
1 shared publication - Jingdong Li
Department of Hepatobiliary Surgery, Academician (Expert) Workstation, Affiliated Hospital of North Sichuan Medical College, Nanchong, China
1 shared publication
Latest Publications
- Open Access
- 16 October 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (42) , e51198
Research trends and hotspots in colorectal cancer screening
Background: Colorectal cancer (CRC), is a highly prevalent malignant tumor worldwide, and early screening is key to improving its prognosis. Currently, CRC screening research is growing exponentially, but its core research hotspots, evolutionary trends, and interdisciplinary features are not clear. In this study, we used bibliometric analysis to analyze the distribution of literature, research hotspots, and cutting-edge developments in the field of CRC screening worldwide, and to provide a scientific basis for optimizing screening strategies. Methods: Publications on CRC screening from 2015 to 2024 were retrieved from the Web of Science Core Collection. VOSviewer (v1.6.20), RStudio (v4.4.1), and CiteSpace (v6.4.2) were used for bibliometric and visual analyses. The main analyses included publication trends, countries, authors, journals, references, and keywords. Result: A total of 3245 publications were included in the analysis. Global publications on CRC screening showed a steady upward trend over the past decade, with an annual growth rate of 2.17%. The United States contributed the highest number of publications, and the University of North Carolina ranked as the most productive institution. GASTROENTEROLOGY and GUT were the most frequently cited journals in this field. Lansdorp‑Vogelaar I was among the most prolific authors. The most cited article was “CRC screening for average-risk adults: 2018 guideline update from the American Cancer Society.” Keyword analysis showed that the research hotspots in this field included colonoscopy, biomarker, adenoma detection rate, artificial intelligence, etc. Conclusion: Current research in CRC screening focuses on traditional screening methods, population-related factors, and emerging technologies, particularly artificial intelligence. Stronger international collaboration and interdisciplinary studies are needed to advance the field.
- 16 October 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (42) , e51198
Open AccessResearch trends and hotspots in colorectal cancer screening
Background: Colorectal cancer (CRC), is a highly prevalent malignant tumor worldwide, and early screening is key to improving its prognosis. Currently, CRC screening research is growing exponentially, but its core research hotspots, evolutionary trends, and interdisciplinary features are not clear. In this study, we used bibliometric analysis to analyze the distribution of literature, research hotspots, and cutting-edge developments in the field of CRC screening worldwide, and to provide a scientific basis for optimizing screening strategies. Methods: Publications on CRC screening from 2015 to 2024 were retrieved from the Web of Science Core Collection. VOSviewer (v1.6.20), RStudio (v4.4.1), and CiteSpace (v6.4.2) were used for bibliometric and visual analyses. The main analyses included publication trends, countries, authors, journals, references, and keywords. Result: A total of 3245 publications were included in the analysis. Global publications on CRC screening showed a steady upward trend over the past decade, with an annual growth rate of 2.17%. The United States contributed the highest number of publications, and the University of North Carolina ranked as the most productive institution. GASTROENTEROLOGY and GUT were the most frequently cited journals in this field. Lansdorp‑Vogelaar I was among the most prolific authors. The most cited article was “CRC screening for average-risk adults: 2018 guideline update from the American Cancer Society.” Keyword analysis showed that the research hotspots in this field included colonoscopy, biomarker, adenoma detection rate, artificial intelligence, etc. Conclusion: Current research in CRC screening focuses on traditional screening methods, population-related factors, and emerging technologies, particularly artificial intelligence. Stronger international collaboration and interdisciplinary studies are needed to advance the field.
- Open Access
- 21 August 2026
- Published by Springer Nature in Hereditas
- Vol. 163 (1)
Epigenetic upregulation of PAPSS2 drives proliferation, migration, angiogenesis, and M2 macrophage infiltration in gastric cancer
Objective: 3’-Phosphoadenosine 5’-phosphosulfate (PAPS) synthase 2 (PAPSS2) catalyzes the rate-limiting step in sulfation metabolism by generating the universal sulfate donor PAPS. However, its biological and clinical significance in gastric cancer (GC) remains poorly understood. Methods: We analyzed PAPSS2 expression, prognostic value, immune infiltration correlates, promoter methylation, and histone acetylation patterns using public databases. Expression levels were validated by qRT-PCR and western blotting. Functional assays —CCK-8, Transwell migration/invasion, and HUVEC tube formation assays— assessed the oncogenic roles of PAPSS2. Finally, we performed ChIP assay to investigate the epigenetic mechanism driving PAPSS2 upregulation in GC. Results: PAPSS2 was significantly upregulated in GC tissues and cell lines, and high PAPSS2 expression correlated with poorer patient survival. Co-expression network analysis linked PAPSS2-associated genes to extracellular matrix organization, angiogenesis, and metastatic progression. Functional knockdown of PAPSS2 suppressed GC cell proliferation, migration, and invasion; impaired VEGFA-driven angiogenesis; and inhibited M2 macrophage polarization. Mechanistically, promoter hypomethylation and p300/CBP-mediated H3K27 acetylation may contribute to PAPSS2 overexpression in GC cells. Conclusion: Epigenetically driven PAPSS2 overexpression promotes GC cell proliferation and migration, potentiates VEGFA-dependent angiogenesis, and facilitates M2 macrophage polarization, highlighting PAPSS2 as a potential therapeutic target in GC.
- 21 August 2026
- Published by Springer Nature in Hereditas
- Vol. 163 (1)
Open AccessEpigenetic upregulation of PAPSS2 drives proliferation, migration, angiogenesis, and M2 macrophage infiltration in gastric cancer
Objective: 3’-Phosphoadenosine 5’-phosphosulfate (PAPS) synthase 2 (PAPSS2) catalyzes the rate-limiting step in sulfation metabolism by generating the universal sulfate donor PAPS. However, its biological and clinical significance in gastric cancer (GC) remains poorly understood. Methods: We analyzed PAPSS2 expression, prognostic value, immune infiltration correlates, promoter methylation, and histone acetylation patterns using public databases. Expression levels were validated by qRT-PCR and western blotting. Functional assays —CCK-8, Transwell migration/invasion, and HUVEC tube formation assays— assessed the oncogenic roles of PAPSS2. Finally, we performed ChIP assay to investigate the epigenetic mechanism driving PAPSS2 upregulation in GC. Results: PAPSS2 was significantly upregulated in GC tissues and cell lines, and high PAPSS2 expression correlated with poorer patient survival. Co-expression network analysis linked PAPSS2-associated genes to extracellular matrix organization, angiogenesis, and metastatic progression. Functional knockdown of PAPSS2 suppressed GC cell proliferation, migration, and invasion; impaired VEGFA-driven angiogenesis; and inhibited M2 macrophage polarization. Mechanistically, promoter hypomethylation and p300/CBP-mediated H3K27 acetylation may contribute to PAPSS2 overexpression in GC cells. Conclusion: Epigenetically driven PAPSS2 overexpression promotes GC cell proliferation and migration, potentiates VEGFA-dependent angiogenesis, and facilitates M2 macrophage polarization, highlighting PAPSS2 as a potential therapeutic target in GC.
- Open Access
- 16 May 2026
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
SLAMF8 promotes tumor growth of gastric cancer by enhancing M2 polarization of tumor-associated macrophages
The signaling lymphocytic activation molecule family member 8 (SLAMF8) is predominantly expressed on the surface of macrophages and participates in modulating tumor immune microenvironment. However, the role of SLAMF8 in tumor-associated macrophages (TAMs) in gastric cancer (GC) remains unclear. SLAMF8 expression and its association with patient prognosis were analyzed using various online databases. CCK-8 and EdU assays were used to assess GC cell proliferation. A xenograft tumor model was used to assess the in vivo functional role of SLAMF8. SLAMF8 expression was markedly increased and correlated with an unfavorable prognosis in GC. Additionally, SLAMF8 was primarily expressed in macrophages in GC tissues and increased in in vitro-generated-TAMs. SLAMF8 knockdown suppressed M2 polarization, whereas SLAMF8 overexpression promoted M2 polarization in in vitro-generated TAMs. SLAMF8 facilitates TAM-like polarization by coordinately inhibiting NF-κB activation and activating the JAK2/STAT3 signaling pathway. Furthermore, SLAMF8-overexpressing TAMs enhanced the growth of MKN-45 cells both in vitro and in vivo and impaired CD8 + T cell function. SLAMF8 promotes macrophage M2 polarization and accelerates CD8 + T cell dysfunction, thereby facilitating the progression of GC.
- 16 May 2026
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
Open AccessSLAMF8 promotes tumor growth of gastric cancer by enhancing M2 polarization of tumor-associated macrophages
The signaling lymphocytic activation molecule family member 8 (SLAMF8) is predominantly expressed on the surface of macrophages and participates in modulating tumor immune microenvironment. However, the role of SLAMF8 in tumor-associated macrophages (TAMs) in gastric cancer (GC) remains unclear. SLAMF8 expression and its association with patient prognosis were analyzed using various online databases. CCK-8 and EdU assays were used to assess GC cell proliferation. A xenograft tumor model was used to assess the in vivo functional role of SLAMF8. SLAMF8 expression was markedly increased and correlated with an unfavorable prognosis in GC. Additionally, SLAMF8 was primarily expressed in macrophages in GC tissues and increased in in vitro-generated-TAMs. SLAMF8 knockdown suppressed M2 polarization, whereas SLAMF8 overexpression promoted M2 polarization in in vitro-generated TAMs. SLAMF8 facilitates TAM-like polarization by coordinately inhibiting NF-κB activation and activating the JAK2/STAT3 signaling pathway. Furthermore, SLAMF8-overexpressing TAMs enhanced the growth of MKN-45 cells both in vitro and in vivo and impaired CD8 + T cell function. SLAMF8 promotes macrophage M2 polarization and accelerates CD8 + T cell dysfunction, thereby facilitating the progression of GC.
- Open Access
- 29 July 2024
- Published by Springer Nature in Discover Oncology
- Vol. 15 (1) , 1-20
Establishment of nomogram to predict overall survival and cancer-specific survival of local tumor resection in patients with colorectal cancer liver metastasis with unresectable metastases: a large population-based analysis
Background and Purpose: The tumour-node metastasis (TNM) classification is a common model for evaluating the prognostic value of tumour patients. However, few models have been used to predict the survival outcomes of patients with colorectal cancer liver metastasis (CRLM) with unresectable metastases who received the primary local surgery. Thus, we utilized the Surveillance, Epidemiology, and End Results (SEER) database to establish novel nomograms for predicting the overall survival (OS) and cancer-specific survival (CSS) of these patients. Methods: Extracted primary data on CRLM patients by local surgery from SEER database. All prognostic factors of OS and CSS were determined by Cox regression analysis. The concordance index (C-index), receiver operating characteristic (ROC) curves and calibration curves were used to further evaluate the accuracy and discrimination of these nomograms. Decision curve analysis (DCA) was executed to evaluate the nomograms for the clinical net benefit. Risk stratification analysis (RSA) was used to evaluate the reliability of them in clinical. Results: 3622 eligible patients were screened and assigned to training cohort (1812) or validation cohort (1810). The age, chemotherapy, tumour grade, primary tumour site, tumour size, lymph node positive rate (LNR), marital status, and carcinoembryonic antigen (CEA) were independent prognostic factors of OS. Additionally, the age, chemotherapy, tumour grade, primary tumour site, tumour size, LNR, and CEA were independent prognostic factors of CSS. The results of C-indexes and ROC curves indicated that the established nomograms exhibited better discrimination power than TNM classification. The calibration curves demonstrated excellent agreement between the predicted and actual survival rates for 1-, 3-, and 5 year OS and CSS. Meanwhile, the validation cohort demonstrated similar results. Background the clinic context, the DCA showed that these nomograms have higher net benefits, and the RSA showed that patients were further divided into low risk, medium risk, and high risk groups according to the predicted scores from nomograms. And, the Kaplan–Meier curve and log-rank test showed that the survival differences among the three groups are statistically significant. Conclusions: The prognostic nomograms showed very high accuracy, identifiability, and clinical practicality in predicting the OS and CSS of CRLM patients with unresectable metastases treated by local surgery at 1-, 3-, and 5 years, which might improve individualized predictions of survival risks and help clinicians formulate treatment plans.
- 29 July 2024
- Published by Springer Nature in Discover Oncology
- Vol. 15 (1) , 1-20
Open AccessEstablishment of nomogram to predict overall survival and cancer-specific survival of local tumor resection in patients with colorectal cancer liver metastasis with unresectable metastases: a large population-based analysis
Background and Purpose: The tumour-node metastasis (TNM) classification is a common model for evaluating the prognostic value of tumour patients. However, few models have been used to predict the survival outcomes of patients with colorectal cancer liver metastasis (CRLM) with unresectable metastases who received the primary local surgery. Thus, we utilized the Surveillance, Epidemiology, and End Results (SEER) database to establish novel nomograms for predicting the overall survival (OS) and cancer-specific survival (CSS) of these patients. Methods: Extracted primary data on CRLM patients by local surgery from SEER database. All prognostic factors of OS and CSS were determined by Cox regression analysis. The concordance index (C-index), receiver operating characteristic (ROC) curves and calibration curves were used to further evaluate the accuracy and discrimination of these nomograms. Decision curve analysis (DCA) was executed to evaluate the nomograms for the clinical net benefit. Risk stratification analysis (RSA) was used to evaluate the reliability of them in clinical. Results: 3622 eligible patients were screened and assigned to training cohort (1812) or validation cohort (1810). The age, chemotherapy, tumour grade, primary tumour site, tumour size, lymph node positive rate (LNR), marital status, and carcinoembryonic antigen (CEA) were independent prognostic factors of OS. Additionally, the age, chemotherapy, tumour grade, primary tumour site, tumour size, LNR, and CEA were independent prognostic factors of CSS. The results of C-indexes and ROC curves indicated that the established nomograms exhibited better discrimination power than TNM classification. The calibration curves demonstrated excellent agreement between the predicted and actual survival rates for 1-, 3-, and 5 year OS and CSS. Meanwhile, the validation cohort demonstrated similar results. Background the clinic context, the DCA showed that these nomograms have higher net benefits, and the RSA showed that patients were further divided into low risk, medium risk, and high risk groups according to the predicted scores from nomograms. And, the Kaplan–Meier curve and log-rank test showed that the survival differences among the three groups are statistically significant. Conclusions: The prognostic nomograms showed very high accuracy, identifiability, and clinical practicality in predicting the OS and CSS of CRLM patients with unresectable metastases treated by local surgery at 1-, 3-, and 5 years, which might improve individualized predictions of survival risks and help clinicians formulate treatment plans.